Ceftriaxone Dosing for Pneumonia

Pediatric Dosing

For most cases of pediatric community-acquired pneumonia, the American Academy of Pediatrics recommends ceftriaxone dosing at 50-100 mg/kg/day given every 12-24 hours 1, 2
For penicillin-resistant S. pneumoniae, the Infectious Diseases Society of America recommends ceftriaxone dosing at 100 mg/kg/day every 12-24 hours 3
For severe infections including empyema, the American Academy of Pediatrics suggests considering higher dosing within the recommended range 2
For S. pneumoniae with penicillin MICs >2.0 μg/mL, the Infectious Diseases Society of America recommends ceftriaxone dosing at 50-100 mg/kg/day every 12-24 hours 3
For Group A Streptococcus, the American Academy of Pediatrics recommends ceftriaxone dosing at 50-100 mg/kg/day every 12-24 hours 3
For H. influenzae (β-lactamase producing), the Infectious Diseases Society of America recommends ceftriaxone dosing at 50-100 mg/kg/day every 12-24 hours 1

The Infectious Diseases Society of America recommends considering adding a macrolide for atypical pathogen coverage (Mycoplasma pneumoniae, Chlamydophila pneumoniae) 2, 4
For suspected MRSA, the Infectious Diseases Society of America suggests adding vancomycin or clindamycin based on local susceptibility patterns 4, 5

The American College of Clinical Pharmacy recommends assessing clinical response within 48-72 hours of initiating therapy 6
The Infectious Diseases Society of America suggests considering step-down to appropriate oral therapy once clinical improvement is observed 1, 3

The American Academy of Pediatrics recommends high-dose amoxicillin (90 mg/kg/day in 2 doses to a maximum of 4 g/day) as the oral therapy for presumed bacterial pneumonia in children ≥5 years old, which can be used following an initial dose of ceftriaxone 7
Initial ceftriaxone followed by high-dose amoxicillin can be effective for teenagers with pneumonia, particularly when transitioning from inpatient to outpatient care or when initiating treatment in an outpatient setting for a patient who may need enhanced initial coverage 7

Clinical improvement should be expected within 48-72 hours of initiating therapy, and this approach is particularly useful when there is concern about medication adherence with the first few critical doses 7, 8
If atypical pneumonia is suspected, consider adding a macrolide as beta-lactams do not cover these pathogens, and for patients with drug allergies to beta-lactams, alternative regimens should be considered 7
This approach should be used selectively and not as routine practice for all cases of pneumonia, and if the patient shows no improvement within 48-72 hours, reevaluation and possible change in therapy is warranted 7, 8